Home
Novartis: More promising data from a Phase 3 trial with AveXis’ gene therapy Zolgensma® for Spinal Muscular Atrophy Type 1

Novartis: More promising data from a Phase 3 trial with AveXis’ gene therapy Zolgensma® for Spinal Muscular Atrophy Type 1

Today’s Highlights April 17, 2019

Novartis Has More Promising Data from Their Phase 3 Gene Therapy Trial with AveXis

AveXis Inc., a Novartis (NVS) company, announced positive interim data from its Phase 3 STR1VE trial of Zolgensma® (onasemnogene abeparvovec-xio (AVXS-101) gene therapy in spinal muscular atrophy (SMA) Type 1.

About Spinal Muscular Atrophy (SMA . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.
Today’s Highlights
, ,
April 17, 2019

Other Articles